A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment

Inclusion Criteria:

• Participant has provided written informed consent and agrees to comply with thestudy protocol.

• Participant with PBC diagnosis.

• Participant for whom the treating physician has decided to start or participants whoare currently receiving treatment with commercialized elafibranor.

• If a participant has a caregiver who agrees to complete the caregiverquestionnaires, an informed consent should be collected from the caregiver beforeany data is collected.

Exclusion Criteria:

• Participant is currently participating or, plans to participate in aninvestigational drug study or medical device study containing active substance.

• Participant with known hypersensitivity to the product or to any of its excipients.

• Participant with mental instability or incompetence, such that the validity ofinformed consent or ability to be compliant with the study is uncertain.